

UPDATES

Securities Class Actions in the Life Sciences Sector

Spring 2022

Sidley is pleased to present its annual year-in-review addressing developments in securities class actions brought against life sciences companies in 2021.

In this publication, we provide an overview and analysis of trends in decisions involving life sciences companies with products at two distinct stages of development — pre- and post-FDA approval. We also summarize each of the reported federal decisions in this area and catalog the new securities class action complaints filed against life sciences companies in 2021.

[Click here](#) to view a two-page summary.

[Click here](#) to download the PDF.

[Click here](#) to order hard copies. Limited supply available.

[View Survey](#) [View Two-Page Summary](#)

CONTACTS

Sara B. Brody , Partner	+1 415 772 1279, sbrody@sidley.com
Robin E. Wechkin , Counsel	+1 415 439 1799, rwechkin@sidley.com
Francesca E. Brody , Partner	+1 212 839 5372, fbrody@sidley.com
Sarah A. Hemmendinger , Partner	+1 415 772 7413, shemmendinger@sidley.com
Matthew J. Dolan , Partner	+1 650 565 7106, mdolan@sidley.com

Sidley provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships as explained at www.sidley.com/disclaimer.

© Sidley Austin LLP